ACR on Air

Rheumatology experts Joan Bathon and Jill Buyon discuss upcoming abstracts in the field. Topics include the use of AI, steroid use, hydroxychloroquine dosing, preventing RA in lupus, pregnancy in lupus, and methotrexate dosing.

Dr. Mary Beth Humphrey, an expert in rheumatology, discusses the new ACR GIOP guidelines in this podcast. The podcast covers topics such as glucocorticoid-induced osteoporosis (GIOP) in rheumatic diseases, screening for osteoporosis in adults and pediatric patients, treating osteoporosis in patients on glucocorticoids, interventions for osteoporosis, and the potential impact of the new guidelines on people with rheumatic diseases.

Experts discuss strategies for recruiting and retaining rheumatology workforce, challenges in rural areas, changes in practice dynamics in Omaha, role of nurse practitioners, bureaucratic hurdles in healthcare, and strategies for reducing burnout in rheumatology.

The podcast features interviews with attendees of Convergence at the San Diego Convention Center, discussing impactful sessions on topics such as lupus genetics, mitochondrial diseases, and imposter syndrome. Speakers also highlight the development of a strategic plan for autoimmune disease research and the importance of networking. They discuss the relaxing activity of making friendship bracelets and express excitement for future conferences.

In this podcast, Dr. Hausmann interviews attendees at the Convergence Annual Meeting. Topics discussed include the benefits of networking at the conference, the experiences of MedPeds physicians, excitement for interprofessional activity and patient engagement at the conference, and interesting sessions on treatment options for PMR, GCA, and lupus.

Award-winning researcher, Dr. Doruk Erkan, discusses new classification criteria for Antiphospholipid Syndrome (APS), highlighting the challenges of diagnosis and the need for further research. The podcast explores the complexity of APS, emphasizes the importance of assessing the antiphospholipid antibody profile, and discusses the limitations of the old criteria. The development of the new classification criteria is discussed, emphasizing the collaborative effort and point-based system. The podcast also touches on the challenges of APS guidelines, the development of criteria for patients needing anticoagulation, and the potential impact on diagnosis and management of ANIFOSFELIPIT syndrome.

Dr. Christina Downey discusses challenges faced by rheumatologists, advocacy efforts in addressing drug pricing and workforce shortages, securing funding for Pediatric Subspecialty Repayment Loan Program, and importance of advocating for rheumatology and patient care. Listeners are encouraged to get involved in ACR's advocacy efforts.

Computational modeling company discusses work with autoimmune disease models and collaborations with pharmaceutical companies. Importance of networking, presenting research, and staying up to date in rheumatology mentioned. Potential impact of AI on healthcare delivery explored, emphasizing importance of human judgment. Experience at ACR conference highlighted, including value for rheumatologists from developing nations. Key takeaways from the congress discussed, including imaging studies in non-radiographic enclosing spondylitis and networking for research collaborations.

Dr. Sindhu Johnson discusses the 2023 ACR guidelines for monitoring and treating interstitial lung disease in rheumatic diseases, including screening methods, monitoring frequency, and treatment options. The chapter highlights the importance of collaborative management between rheumatologists and pulmonologists, explores various treatment options and recommendations for specific conditions, and emphasizes the importance of early detection.

Dr. Thomas Ortel explains thrombotic microangiopathy (TMA) and its significance for rheumatology. The podcast covers the association between TMAs and rheumatologic conditions, management and diagnosis of hemolytic uremic syndrome in lupus patients, recognition and treatment of TTP, mechanisms of thrombotic microangiopathy, non-criteria manifestations of Antiphospholipid Syndrome, and the future of TMAs in autoimmune conditions.